If these receptors on tumor cells are similarly inhibited by RANKL, then inhibition of RANKL by denosumab would increase their expression and enhance pro-tumoral signaling by the osteoid cell-derived chemokines CCL2, CCL5, CXCL16, and CX3CL1. This evidence concerns the gene CCL5 and neoplasm.